Can you take GHRP-2 and MK-677 (Ibutamoren) together?

There is no specific, well-documented interaction rule for combining GHRP-2 and MK-677 (Ibutamoren) in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, GHRP-2 or MK-677 (Ibutamoren)?

GHRP-2 is currently preclinical only and MK-677 (Ibutamoren) is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

GHRP-2 vs MK-677 (Ibutamoren)

Q: What is the difference between GHRP-2 and MK-677 (Ibutamoren)?

GHRP-2: GHRP-2 is a synthetic hexapeptide that acts as a ghrelin mimetic, stimulating the pituitary gland to secrete growth hormone (GH). It is one of the most potent GH secretagogues studied, producing stronger GH pulses than GHRP-6 with comparatively less appetite stimulation. MK-677 (Ibutamoren): Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GHRP-2

Preclinical only

GHRP-2 is a synthetic hexapeptide that acts as a ghrelin mimetic, stimulating the pituitary gland to secrete growth hormone (GH). It is one of the most potent GH secretagogues studied, producing stronger GH pulses than GHRP-6 with comparatively less appetite stimulation.

Full profile

MK-677 (Ibutamoren)

Research-stage

Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.

Full profile

	GHRP-2	MK-677 (Ibutamoren)
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	Growth Hormone Releasing Peptide-2, Pralmorelin, KP 102	Ibutamoren, Nutrobal, MK677, L-163,191
Evidence	Preclinical only	Research-stage
Dosing range	100mcg–300mcg mcg, 1–3 times daily, on an empty stomach	10mg–50mg mg, once daily oral
Administration	Subcutaneous injection, Intramuscular injection	Oral (capsule/liquid)
Key side effects	Increased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritation	Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient)
Cited sources	3 references	2 references

Key differences

Evidence level differs: GHRP-2 is preclinical only, while MK-677 (Ibutamoren) is research-stage.
Administration: GHRP-2 — Subcutaneous injection, Intramuscular injection; MK-677 (Ibutamoren) — Oral (capsule/liquid).
Dosing units differ: GHRP-2 is dosed in mcg, MK-677 (Ibutamoren) in mg — they operate at different scales.
Frequency: GHRP-2 is typically 1–3 times daily, on an empty stomach; MK-677 (Ibutamoren) is once daily oral.
Research depth: this profile cites 3 sources for GHRP-2 vs 2 for MK-677 (Ibutamoren).

How each works

GHRP-2

GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.

MK-677 (Ibutamoren)

MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.

Read the full GHRP-2 profile Read the full MK-677 (Ibutamoren) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.